

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT6633247

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
BIOFOURMIS AG	02/04/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	BIOSIGNS PTE LTD.
<b>Street Address:</b>	2 VENTURE DRIVE #23-01
<b>City:</b>	VISION EXCHANGE
<b>State/Country:</b>	SINGAPORE
<b>Postal Code:</b>	608526
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	29629657
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(312)427-6663
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	3124271300
<b>Email:</b>	ChicagoUSPTO@ladas.net
<b>Correspondent Name:</b>	RICHARD J. STREIT
<b>Address Line 1:</b>	LADAS & PARRY, 224 SOUTH MICHIGAN AVE.
<b>Address Line 4:</b>	CHICAGO, ILLINOIS 60604
<b>ATTORNEY DOCKET NUMBER:</b>	CU-73560 RJS/MB
<b>NAME OF SUBMITTER:</b>	RICHARD J. STREIT
<b>SIGNATURE:</b>	/Richard J. Streit/
<b>DATE SIGNED:</b>	03/31/2021
<b>Total Attachments: 18</b>	
source=CU-73560_Assignment_Agreement_bt看_Biofourmis_and_Biosigns#page1.tif	
source=CU-73560_Assignment_Agreement_bt看_Biofourmis_and_Biosigns#page2.tif	
source=CU-73560_Assignment_Agreement_bt看_Biofourmis_and_Biosigns#page3.tif	
source=CU-73560_Assignment_Agreement_bt看_Biofourmis_and_Biosigns#page4.tif	
source=CU-73560_Assignment_Agreement_bt看_Biofourmis_and_Biosigns#page5.tif	
source=CU-73560_Assignment_Agreement_bt看_Biofourmis_and_Biosigns#page6.tif	

source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page7.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page8.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page9.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page10.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page11.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page12.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page13.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page14.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page15.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page16.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page17.tif  
source=CU-73560\_Assignment\_Agreement\_bt看\_Biofourmis\_and\_Biosigns#page18.tif

---

Between

**BIOFOURMIS AG**

and

**BIOSIGNS PTE LTD.**

---

**ASSIGNMENT AGREEMENT**

---

## ASSIGNMENT OF INTELLECTUAL PROPERTY RIGHTS

THIS AGREEMENT is made on the 4<sup>th</sup> day of February 2020.

### PARTIES:

1. **BIOFOURMIS AG**, a company incorporated under the laws of Switzerland, of the address c/o Biovotion AG, Kreuzstrasse 2, 8008 Zurich, Switzerland (the 'Assignor') of the one part; and
2. **BIOSIGNS PTE LTD.**, a company incorporated under the laws of Singapore, of the address 2 Venture Drive, #23-01 Vision Exchange, Singapore 608526 (the 'Assignee') of the other part.

### BACKGROUND:

- (a) The Assignor is the sole beneficial owner of all intellectual property rights in all patents, trademarks, registered designs, copyrights and domain names set out in Annex 1 (the "Intellectual Property Rights"); and
- (b) The Assignor has agreed to assign all its right, title and interest in and to the Intellectual Property Rights to the Assignee on the terms set out in this Agreement.

**IT IS NOW AGREED** as follows:

### 1. ASSIGNMENT

- 1.1 Pursuant to the terms of this Agreement and in consideration of the sum of S\$1 (One Singapore Dollar) paid by the Assignee to the Assignor (the receipt of which the Assignor expressly acknowledges) the Assignor hereby assigns to the Assignee absolutely all its right, title and interest in and to the Intellectual Property Rights and the full and exclusive benefit thereof, and in and to all and any inventions disclosed in any applications filed and in any patents granted thereafter in any jurisdiction, including:-

- (a) In respect of the Intellectual Property Rights:
  - i. the right to claim priority from and to prosecute and obtain the grant and/or the registration of the Intellectual Property Rights;
  - ii. the right to file any divisional applications, continuation applications and continuation-in-part applications based thereon and to prosecute

- and obtain grant of the Intellectual Property Rights on each and any such divisional applications, continuation applications and continuation-in-part applications; and
- iii. the absolute entitlement to any Intellectual Property Rights or other similar forms of protection granted in respect of the Intellectual Property Rights; and

(b) the right to bring, make, oppose, defend, appeal proceedings, claims or actions and obtain relief (and to retain any damages recovered) in respect of any infringement, or any other cause of action arising from the ownership of the Intellectual Property Rights whether occurring before on or after the date of this Agreement.

- 1.2 In the event that the validity of the Intellectual Property Rights is challenged on any point upon which the Assignor has or can procure information or advice which may assist in meeting and defeating or reducing the effect of such challenge, the Assignor agrees and/or undertakes to supply or procure the supply of such information and/or advice without unreasonable delay but subject to the right to charge the Assignee out-of-pocket expenses properly and reasonably incurred in pursuance of this provision.

## **2. EFFECTIVE DATE**

- 2.1 The effective date of this assignment shall be the date of this Agreement.

## **3. FURTHER ASSURANCE**

- 3.1 The Assignor will at all times at the request and reasonable cost of the Assignee execute all such instruments and do all such things as may be necessary or reasonably appropriate for the carrying out of this Agreement or to secure the vesting in the Assignee of the rights agreed to be assigned hereunder.

## **4. COUNTERPARTS**


- 4.1 This Agreement may be executed in any number of counterparts, each of which when executed shall constitute a duplicate original, but all the counterparts shall together constitute the one agreement.
- 4.2 No counterpart shall be effective until each party has executed at least one counterpart.


**5. GOVERNING LAW AND JURISDICTION**

5.1 This Agreement shall be governed by and construed in accordance with Singapore law and all parties agree irrevocably to submit to the exclusive jurisdiction of the Singapore courts to settle any disputes that may arise in connection with this Agreement.


**IN WITNESS WHEREOF** this Agreement has been executed the date and year first above written.


Signed by Kuldeep Singh Rajput  
Position: Director  
duly authorized for and on behalf of the Assignor  
**BIOFOURMIS AG**

)  
)  
)  
)  



in the presence of:  
  
Witness: Shiela Shah  
Position: Office Manager


Signed by Wendou NIU  
Position: Director  
duly authorized for and on behalf of the Assignee  
**BIOSIGNS PTE LTD.**

)  
)  
)  
)  



in the presence of:  
  
Witness: Shiela Shah  
Position: Office Manager


**Annex 1: Intellectual Property Rights**













5



9




7




**B. Designs**

Title	Country	Class	Designations	Priority Claim	Application No. and Date	Registration No. and Date
[Redacted Content]						


Title	Country	Class	Designations	Priority Claim	Application No. and Date	Registration No. and Date
1. Medical monitoring device; 2. Medical monitoring device with armband; 3. Medical monitoring device; 4. Medical monitoring device with armband	International Design Registration	24-02				
				US	CH 141992 (16-Nov-15)	35/501,817 (13-May-16)


Title	Country	Class	Designations	Priority Claim	Application No. and Date	Registration No. and Date
[REDACTED]						
					29/629,657 (Continuation of 35/501, 817) (13-May-16)	Not published





11





14

